Department of Economic and Social Affairs. World Population Prospects 2024. United Nations https://population.un.org/wpp/ (2024).

Global Health Observatory. Global Health Estimates 2020: Life expectancy and leading causes of death and disability. World Health Organization https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death (2020).

Global Health Observatory. Age-standardized rate per 100000 by region. IARC https://gco.iarc.fr/today/en/dataviz (2022).

Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 78, 1966–1986 (2023).

Article  Google Scholar 

Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J. Hepatol. 73, 202–209 (2020).

Article  PubMed  Google Scholar 

Méndez-Sánchez, N. et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol. Hepatol. 7, 388–390 (2022).

Article  PubMed  Google Scholar 

Song, S. J., Lai, J. C., Wong, G. L., Wong, V. W. & Yip, T. C. Can we use old NAFLD data under the new MASLD definition? J. Hepatol. 80, e54–e56 (2024).

Article  PubMed  Google Scholar 

Arora, U., Biswas, S., Aggarwal, S. & Duseja, A. Shalimar. MASLD screening and diagnostic algorithms are interchangeable with existing NAFLD literature. J. Hepatol. 80, e89–e91 (2024).

Article  PubMed  Google Scholar 

Miao, L., Ye, S. M. & Zheng, M. H. “Fatty” or “steatotic”: position statement from a linguistic perspective by the Chinese-speaking community. J. Hepatol. https://doi.org/10.1016/j.jhep.2024.05.031 (2024).

Ramírez-Mejía, M. M., Jiménez-Gutiérrez, C., Eslam, M., George, J. & Méndez-Sánchez, N. Breaking new ground: MASLD vs. MAFLD – which holds the key for risk stratification? Hepatol. Int. 18, 168–178 (2024).

Article  PubMed  Google Scholar 

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 Lancet 392 1789 1858 (2018).

Article  Google Scholar 

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1204–1222 (2020).

Article  Google Scholar 

World Health Organization. Roadmap for health and well-being in Central Asia (2022–2025) (WHO, 2022).

Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2021 (GBD 2021): Results (IHME, 2022).

Lan, Y. et al. The burden of liver cirrhosis and underlying etiologies: results from the Global Burden of Disease Study 2019. Hepatol. Commun. 7, e0026 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Tan, D. et al. Global epidemiology of cirrhosis: changing etiological basis and comparable burden of nonalcoholic steatohepatitis between males and females. Dig. Dis. 41, 900–912 (2023).

Article  PubMed  Google Scholar 

Paik, J. et al. The global burden of liver cancer (LC) and chronic liver diseases (CLD) is driven by non-alcoholic steatohepatitis (NASH) and alcohol liver disease (ALD) [abstract GS008] J. Hepatol. 77, (Suppl. 1) 5–7 (2022).

Article  Google Scholar 

Philips, C. A., Augustine, P., Rajesh, S., Y, P. K. & Madhu, D. Complementary and alternative medicine-related drug-induced liver injury in Asia. J. Clin. Transl. Hepatol. 7, 263–274 (2019).

PubMed  PubMed Central  Google Scholar 

Devarbhavi, H. et al. Drug-induced acute-on-chronic liver failure in Asian patients. Am. J. Gastroenterol. 114, 929–937 (2019).

Article  PubMed  Google Scholar 

Sherman, M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin. Liver Dis. 25, 143–154 (2005).

Article  PubMed  Google Scholar 

Hsu, Y. C., Huang, D. Q. & Nguyen, M. H. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat. Rev. Gastroenterol. Hepatol. 20, 524–537 (2023).

Article  PubMed  Google Scholar 

Polaris Observatory Collaborators Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study Lancet Gastroenterol. Hepatol. 8, 879–907 (2023).

Article  Google Scholar 

Hyams, K. C. Risks of chronicity following acute hepatitis B virus infection: a review. Clin. Infect. Dis. 20, 992–1000 (1995).

Article  CAS  PubMed  Google Scholar 

Syangbo, A. et al. Associations between the prevalence of chronic hepatitis B among people who inject drugs and country-level characteristics: an ecological analysis. Drug Alcohol Rev. 42, 569–581 (2023).

Article  PubMed  PubMed Central  Google Scholar 

GBD Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol. Hepatol. 7, 796–829 (2022).

Article  Google Scholar 

Schmit, N., Nayagam, S., Thursz, M. R. & Hallett, T. B. The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups. Int. J. Epidemiol. 50, 560–569 (2021).

Article  PubMed  Google Scholar 

Simonetti, J. et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 51, 1531–1537 (2010).

Article  PubMed  Google Scholar 

Polaris Observatory HCV Collaborators Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study Lancet Gastroenterol. Hepatol. 7 396 415 (2022).

Article  Google Scholar 

Goel, A., Rewari, B. B., Sharma, M., Konath, N. M. & Aggarwal, R. Seroprevalence and burden of hepatitis C virus infection in WHO South-East Asia region: a systematic review. J. Gastroenterol. Hepatol. 37, 964–972 (2022).

Article  PubMed  Google Scholar 

Degenhardt, L. et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob. Health 5, e1192–e1207 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Magri, M. C. et al. Hepatitis C among people who inject drugs (PWID) in Latin America and the Caribbean: a meta-analysis of prevalence over three decades. J. Stud. Alcohol Drugs 84, 118–127 (2023).

Article  PubMed  Google Scholar 

Wiessing, L. et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS ONE 9, e103345 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Aghaei, A. M. et al. Prevalence of injecting drug use and HIV, hepatitis B, and hepatitis C in people who inject drugs in the Eastern Mediterranean region: a systematic review and meta-analysis. Lancet Glob. Health 11, e1225–e1237 (2023).

Article  CAS  PubMed  Google Scholar 

Jaacks, L. M. et al. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol. 7, 231–240 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77, 1335–1347 (2023).

Article  PubMed  Google Scholar 

Li, J. et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 4, 389–398 (2019).

Article  PubMed  Google Scholar 

Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7, 851–861 (2022).

Article  PubMed  Google Scholar 

Le, M. H. et al. 2019 global NAFLD prevalence: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 20, 2809–2817.e28 (2022).

Article  PubMed  Google Scholar 

Wu, Y. et al. The epidemiology of NAFLD in mainland China with analysis by adjusted gross regional domestic product: a meta-analysis. Hepatol. Int. 14, 259–269 (2020).

Article  PubMed  Google Scholar 

Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 71, 793–801 (2019).

Article  PubMed